|
| 35981897 | Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using <sup>213</sup>Bi-Anti-CD20 Monoclonal Antibody. | J Nucl Med | 2023 |
| 36809052 | Immunotherapy for Cancer: Something Old, Something New. | Cancer Biother Radiopharm | 2023 |
| 33277392 | Agent Optimization: Absorption, Distribution, Metabolism, Excretion, Dose, and Decay. | J Nucl Med | 2021 |
| 31253744 | Preclinical Evaluation of <sup>203/212</sup>Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. | J Nucl Med | 2020 |
| 32944719 | Reply to the 'Comment on "Investigation of Zr(iv) and <sup>89</sup>Zr(iv) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging"' by A. Bianchi and M. Savastano, Chem. Commun., 2020, 56, D0CC01189D. | Chem Commun (Camb) | 2020 |
| 32503377 | Targeted α-Therapy. | Cancer Biother Radiopharm | 2020 |
| 32275165 | <sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. | Cancer Biother Radiopharm | 2020 |
| 31211593 | "Controls? Controls?? We Don't Need No Stinkin' Controls!" | Cancer Biother Radiopharm | 2019 |
| 29466033 | A New Era of Cancer Biotherapy and Radiopharmaceuticals. | Cancer Biother Radiopharm | 2018 |
| 29916748 | Exploration of a F(ab')<sub>2</sub> Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy. | Cancer Biother Radiopharm | 2018 |
| 29916746 | On Reviewing. | Cancer Biother Radiopharm | 2018 |
| 30199276 | Two Days at the Hunter College Symposium on Radiometals in New York City. | Cancer Biother Radiopharm | 2018 |
| 29641254 | More Thoughts on Standards and Reproducibility. | Cancer Biother Radiopharm | 2018 |
| 28577439 | Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab. | Transl Oncol | 2017 |
| 28338136 | Investigation of the complexation of <sup>nat</sup>Zr(iv) and <sup>89</sup>Zr(iv) by hydroxypyridinones for the development of chelators for PET imaging applications. | Dalton Trans | 2017 |
| 28964629 | Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies. | Bioorg Med Chem | 2017 |
| 28675216 | Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease. | Dalton Trans | 2017 |
| 27030023 | Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. | MAbs | 2016 |
| 27305065 | Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts. | Chemistry | 2016 |
| 27230930 | (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. | J Nucl Med | 2016 |
| 27196891 | Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. | Int J Mol Sci | 2016 |
| 27192116 | The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. | Oncotarget | 2016 |
| 27467592 | Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model. | PLoS One | 2016 |
| 26983636 | Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. | EJNMMI Res | 2016 |
| 25587678 | Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. | MAbs | 2015 |
| 26438866 | 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. | Proc Natl Acad Sci U S A | 2015 |
| 26858987 | Application of <sup>212</sup>Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. | AIMS Med Sci | 2015 |
| 26124477 | Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. | J Clin Oncol | 2015 |
| 26230702 | Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial. | Pharmaceuticals (Basel) | 2015 |
| 26213947 | Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial. | Pharmaceuticals (Basel) | 2015 |
| 25870133 | Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent. | Bioorg Med Chem Lett | 2015 |
| 25945808 | First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting. | Cancer Biother Radiopharm | 2015 |
| 25722448 | Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. | J Nucl Med | 2015 |
| 24761300 | Wide-field in vivo background free imaging by selective magnetic modulation of nanodiamond fluorescence. | Biomed Opt Express | 2014 |
| 25243604 | In vitro and in vivo analysis of indocyanine green-labeled panitumumab for optical imaging-a cautionary tale. | Bioconjug Chem | 2014 |
| 25268703 | Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel. | PLoS One | 2014 |
| 24740517 | Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). | Chemistry | 2014 |
| 23075373 | Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. | Cancer Biother Radiopharm | 2013 |
| 24403230 | Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model. | Cancer Med | 2013 |
| 24045184 | Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. | Clin Cancer Res | 2013 |
| 23632482 | 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. | Br J Cancer | 2013 |
| 23602604 | Methodology for labeling proteins and peptides with lead-212 (212Pb). | Nucl Med Biol | 2013 |
| 23657262 | Surface-engineered nanomaterials as X-ray absorbing adjuvant agents for Auger-mediated chemo-radiation. | Nanoscale | 2013 |
| 23758610 | Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. | Cancer Biother Radiopharm | 2013 |
| 23581827 | Silica encapsulation of fluorescent nanodiamonds for colloidal stability and facile surface functionalization. | J Am Chem Soc | 2013 |
| 23541026 | Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. | Nucl Med Biol | 2013 |
| 23230321 | Molecular pathways: targeted α-particle radiation therapy. | Clin Cancer Res | 2013 |
| 23200172 | Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. | Int J Radiat Oncol Biol Phys | 2013 |
| 23250287 | Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. | Chem Commun (Camb) | 2013 |
| 23329660 | Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. | Radiology | 2013 |